NovaBay lands seven new patents
June 1, 2012 by leonardzehr · Leave a Comment
NovaBay Pharmaceuticals (AMEX:NBY) has received three new composition-of-matter patents in Australia, New Zealand and Mexico, and four Notices of Allowance in Canada, Japan, South Africa and Mexico on its proprietary Aganocide compounds, which includes its lead anti-bacterial and anti-viral, NVC-422.
Different topical formulations of NVC-422 are in mid-to-late-stage clinical development in ophthalmology, dermatology and urology.
These newly issued patents will give composition-of-matter exclusivity for NVC-422 until August of 2024 in Australia, New Zealand and Mexico. The Canadian and Japanese patent offices have given Notices of Allowance for the corresponding patent applications in those countries.
“These seven new patents … not only validate the innovative nature of our science but also enable us to develop what we believe will be a powerful tool in the fight against highly drug-resistant infections,” CEO Ron Najafi said in a statement.
NVC-422 is now patent protected in the U.S. until 2026 and 2024 elsewhere, and can address major segments of the $100 billion global market for anti-infectives, he added.
In addition to NVC-422, these patents cover additional Aganocide compounds and form the basis for a pipeline of non-antibiotic, anti-infective compounds to treat topical infections.
